Web Research

The internet reveals a deeply polarized investment story that financial filings alone cannot tell: Centene suffered a historic 40% single-day stock crash in July 2025 after withdrawing guidance due to flawed actuarial assumptions, triggering an active securities fraud class action lawsuit – yet sophisticated value investors like David Einhorn are aggressively accumulating shares, calling CNC a "coiled spring" turnaround. The web exposes a company where the bearish case (Goldman Sachs Sell rating, congressional ACA fraud investigation, $6.7B goodwill impairment) and the bullish case (deep value at 3.8x EV/EBITDA, CEO insider buying at the 52-week low, 2026 EPS guidance above consensus) are both credible, creating a binary outcome stock heading into Q1 2026 earnings on April 28.

What Matters Most

Stock Price (Apr 24)

$41.82

Avg Analyst Target

$43.47

EV/EBITDA

3.79

Levered FCF (TTM, $B)

5.05

1. Historic 40% Single-Day Crash Triggered by Flawed Actuarial Assumptions (July 2, 2025)

On July 2, 2025, Centene withdrew its full-year 2025 guidance after an independent actuarial review revealed Marketplace enrollment growth was "lower than expected" and morbidity levels were "materially inconsistent with" earlier assumptions. The stock fell from $56.65 to $33.78 in a single session – a 40.4% decline wiping out more than $11 billion in shareholder value. The $1.8 billion deficit reduced EPS by $2.75/share. Jim Cramer called it "one of the most horrible stocks in the group." This was the worst single-day performance in Centene's history. (Forbes, Seeking Alpha, Investopedia)

**Red Flag:** Management's internal actuarial assumptions were materially wrong on their largest growth segment. The scale and speed of the guidance withdrawal raises serious questions about risk management and forecasting credibility.

2. Active Securities Fraud Class Action Lawsuit

Multiple law firms (Hagens Berman, Kessler Topaz, Levi and Korsinsky, Rosen Law, Faruqi and Faruqi) filed a federal securities fraud class action covering the period December 12, 2024 through June 30, 2025. Plaintiffs allege Centene and senior officers "repeatedly made false and misleading public statements" – projecting robust enrollment and favorable morbidity that were "at odds with the company's internal data." The SEC is reportedly investigating whether Centene knew about the flawed assumptions and failed to disclose the risks. As of April 2026, Bronstein Gewirtz and Grossman is still investigating. (PRNewswire, TipRanks)

**Litigation Overhang:** Securities fraud class action is active with multiple law firms. Alleged violations under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. SEC investigation reportedly ongoing.

3. $6.7 Billion Goodwill Impairment – Largest in Company History

In Q3 2025, Centene recorded a $6.7 billion non-cash goodwill impairment triggered by the One Big Beautiful Bill Act and the stock price decline. Combined with a $513 million Magellan Health divestiture impairment, full-year GAAP diluted loss per share was $(13.53) versus adjusted EPS of $2.08. The original 2025 EPS guidance of $7.25 was slashed to $1.75 mid-year before landing at $2.08 adjusted. Of the original $17.5B in goodwill from WellCare and other acquisitions, $10.8B remains on the balance sheet – a potential source of further impairment risk. (Investor Relations, StockTitan)

**Balance Sheet Risk:** $10.8B of goodwill remains after the $6.7B write-down. Further impairment is possible if the stock price stays depressed or if Medicaid/Medicare segment performance deteriorates.

4. 2026 Turnaround Guidance: Adjusted EPS Above $3.00

On February 6, 2026, Centene guided 2026 adjusted diluted EPS above $3.00 – representing more than 40% growth over FY2025's $2.08. Reuters noted Centene was "setting itself apart from peers that have warned of persistent pressure from elevated medical costs." The guidance was above street expectations at the time, though revenue guidance of $186.5-190.5B implies a decline from 2025's $194.8B as the company sheds unprofitable Marketplace members. Management reaffirmed this guidance on March 10, 2026 and redeemed debt notes. (Reuters, TipRanks)

**Positive Signal:** 2026 EPS guidance above $3.00 was above consensus expectations. Management reaffirmed on March 10 despite continued headwinds, signaling confidence in margin recovery.

5. David Einhorn Aggressively Accumulating – "Coiled Spring" Thesis

Greenlight Capital's David Einhorn opened a CNC position in Q4 2024 with approximately 870K shares, growing it to over 2.6 million shares by Q4 2025 – a roughly 70% increase quarter-over-quarter. Einhorn cites a "coiled spring" thesis: Medicaid and ACA rates that lagged inflation in 2025 will realign in 2026, unlocking significant earnings power. Robeco Institutional Asset Management also increased its stake by 426.8% to 2.3 million shares (~$95M) in Q4 2025. Meanwhile, Norges Bank reduced its position by 69.5% (18.4M shares) and UBS Asset Management cut by 75.6% (14.8M shares). (Yahoo Finance, Daily Political)

**Smart Money Signal:** Einhorn's "coiled spring" thesis and aggressive accumulation is a meaningful positive signal. However, major institutional sellers (Norges Bank, UBS AM) provide the counter-narrative.

6. ACA Subsidy Expiration Threatens Marketplace Business

Enhanced ACA premium tax credits (EAPTCs) have expired. According to CNBC, 9% of ACA enrollees became uninsured after enhanced subsidies ended (March 19, 2026). The Wall Street Journal reported that 1 in 7 ACA enrollees failed to make payments in 2026 (April 15, 2026). A 26-year-old enrollee reported premiums spiking $700 after subsidies ended. Centene's Marketplace membership is projected to decline from 5.5M to approximately 3.5M members, a 35% drop, with the remaining pool likely sicker and more costly. (CNBC, WSJ via TipRanks)

**Policy Risk:** ACA subsidy expiration is a direct threat to CNC's second-largest segment. Membership decline plus adverse selection (sicker remaining pool) could pressure Marketplace margins even after 2025's repricing actions.

7. Congressional Subpoena – ACA Fraud Investigation

House Judiciary Committee Republicans have subpoenaed eight ACA health insurers, including Centene, for documents as part of an investigation into potential fraud surrounding Obamacare subsidies. This is separate from the securities fraud class action and represents an additional governance and regulatory risk. No findings or settlements have been publicly disclosed as of April 2026. (Reuters)

**Regulatory Risk:** Congressional investigation adds to the already significant litigation and regulatory overhang. Outcome is uncertain but could result in fines, clawbacks, or operational restrictions.

8. Goldman Sachs Sell Rating vs. Barclays/Bernstein Buy

Analyst sentiment is deeply divided. Goldman Sachs maintains a rare Sell rating with a price target of $32 (lowered from $38 in March 2026). In contrast, Barclays upgraded to Overweight with a $54 target in January 2026 and Bernstein rates CNC Outperform with a $59 target. The consensus is Hold (5 Buy, 13 Hold, 2-3 Sell) with a median target of $41.00. This divergence reflects fundamental disagreement about whether medical cost trends are stabilizing or structurally elevated. (Tickernerd, Yahoo Finance)

No Results

Page / 2 10 of 12 records

9. Medical Cost Pressure Remains Elevated

FY2025 health benefits ratio (HBR) hit 91.9%, up from 88.3% in FY2024, driven by higher Marketplace morbidity, Inflation Reduction Act PDP changes, and Medicaid behavioral health and drug costs. Q4 2025 HBR reached 94.3% (vs. 89.6% in Q4 2024). Reuters noted on February 6, 2026: "High medical costs keep Centene shares under pressure." A new headwind: hospitals are using AI-driven revenue software to aggressively trigger reimbursement claims against insurers, adding cost pressure. Management guides 2026 HBR of 90.9%-91.7%, implying improvement but still elevated versus historical norms. (Reuters, Reuters AI billing)

10. Medicaid Funding Cuts Under Trump Budget Bill

The GOP "Big Beautiful Bill" is expected to impose work requirements, stricter eligibility, and lower federal funding for Medicaid, potentially causing millions to lose coverage. Estimates suggest up to $1 trillion in Medicaid cuts. As Centene's largest segment (64% of membership), any structural reduction in Medicaid enrollment or per-member funding directly impacts revenue and margins. (CNBC, Healthcare Dive)

11. CMS Medicare Advantage 2027 Rates: Better-Than-Feared

On April 6, 2026, CMS finalized 2027 Medicare Advantage payment rates with a 2.48% average increase, described as "better-than-feared" by analysts. CNC stock jumped 5% on the news. This is a positive catalyst for Centene's Medicare strategy, particularly as the company improves Star ratings (46% of members and plans at or above 3.5 stars, up from 23%). (TipRanks, CNBC)

**Positive Catalyst:** CMS 2027 MA rates at +2.48% provide a tailwind for Centene's Medicare turnaround strategy. Star rating improvements further support margin recovery.

12. CEO Insider Buying at 52-Week Low

CEO Sarah London purchased 19,230 shares at $25.50 on August 8, 2025 – one day after CNC hit its 52-week low of $25.08. Board member Theodore Samuels also bought 9,000 shares near the trough. No material insider selling has been detected, aside from routine RSU vesting tax withholdings and Director Kenneth Burdick selling 66,007 shares over six months. The CEO's open-market purchase at the worst point in the stock's history is a meaningful alignment signal. (StockTitan SEC filings, Fintel)

Recent News Timeline

No Results

Page / 2 15 of 22 records

What the Specialists Asked

Insider Spotlight

No Results

CEO Sarah London purchased 19,230 shares at $25.50 on August 8, 2025, one day after the stock hit its 52-week low of $25.08. This approximately $490K open-market buy at the trough of a historic crisis is a meaningful alignment signal. She also holds 13,449 performance stock options at an $81.85 strike requiring the stock to close at or above $100 for 20 consecutive days – currently deep out-of-the-money. Total direct ownership represents 0.052% of shares outstanding, with 93.2% of her ~$20.6M total compensation tied to equity and bonuses rather than salary.

Director Kenneth Burdick is the notable seller, disposing of 66,007 shares over six months for approximately $2.58M. However, Burdick was one of the five directors installed by Politan Capital in the 2021 activism campaign, and his selling may reflect liquidity needs rather than bearish conviction.

No panic insider selling has been detected across the C-suite or board during the 2025 crisis, which is a positive governance signal given the severity of the stock decline.

No Results

The institutional ownership picture is mixed. AQR Capital added 17.1M shares (+117%) while David Einhorn's Greenlight Capital grew its position to 2.6M+ shares. On the selling side, Norges Bank removed 18.4M shares (-69.5%) and UBS Asset Management cut 14.8M shares (-75.6%). Politan Capital, the activist that drove the 2021 board overhaul, has largely exited with a 70.4% reduction. Total institutional ownership remains high at 93.63%.

Industry Context

Structural Medicaid Risk: The GOP "Big Beautiful Bill" poses the most significant long-term structural risk to Centene's dominant Medicaid franchise. Work requirements, stricter eligibility verification, and reduced federal funding could shrink the addressable Medicaid population by millions. As the nation's largest Medicaid insurer, Centene has the most absolute exposure of any managed care company.

ACA Marketplace Contraction: The expiration of enhanced advance premium tax credits is reshaping the individual insurance market. The remaining enrollment pool skews sicker and lower-income, increasing adverse selection risk. Centene is the largest Marketplace insurer through its Ambetter brand, making this a company-specific headwind more than an industry one.

Medicare Advantage Tailwind: CMS finalized 2027 Medicare Advantage rates at +2.48%, described as "better-than-feared." The Trump administration's Medicare GLP-1 drug plan is expected to cost insurers billions (Bloomberg, April 2, 2026), but the net rate environment is improving. Centene is pivoting toward higher-margin Medicare Advantage and dual-eligible (D-SNP) populations, launching an integrated model across 8 states for January 2026.

Hospital AI Billing: A new industry-wide cost pressure identified in web research: hospitals are deploying AI-driven revenue cycle software to aggressively trigger reimbursement claims against insurers (Reuters, March 12, 2026). This represents an emerging cost driver that could offset managed care companies' own AI-driven cost containment investments.

Competitive Positioning: Centene trades at a dramatic discount to managed care peers.

No Results

Centene's EV/EBITDA of 3.8x compares to an industry median of approximately 10.5x. If earnings normalize toward the $6-7 EPS range management achieved in FY2024, the stock could re-rate significantly – but that normalization is contingent on successful execution across Marketplace margin recovery, Medicaid rate catch-up, and Medicare turnaround. The Q1 2026 earnings report on April 28, 2026, is the next critical data point for validating or invalidating this thesis.